Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Coherus Bio (CHRS)

Coherus Bio (CHRS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Coherus BioSciences Initiates Phase 2 Study of Casdozokitug Combined with Toripalimab and Bevacizumab for Liver Cancer Treatment Quiver Quantitative, Inc. - Wed Dec 18, 5:56PM CST

Coherus BioSciences initiates a Phase 2 study evaluating casdozokitug, toripalimab, and bevacizumab for liver cancer treatment.Quiver AI SummaryCoherus BioSciences has launched a randomized Phase 2 study...

CHRS : 1.4700 (+2.80%)
Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025 GlobeNewswire - Wed Dec 18, 7:30AM CST

CHRS : 1.4700 (+2.80%)
Coherus Announces Agreement to Divest UDENYCA® Franchise for up to $558 million to Intas Pharmaceuticals Ltd. GlobeNewswire - Tue Dec 3, 6:00AM CST

CHRS : 1.4700 (+2.80%)
Coherus Management to Participate in the 2024 Citi Global Healthcare Conference GlobeNewswire - Wed Nov 27, 3:01PM CST

CHRS : 1.4700 (+2.80%)
Coherus BioSciences: Q3 Earnings Snapshot AP - Wed Nov 6, 3:11PM CST

Coherus BioSciences: Q3 Earnings Snapshot

CHRS : 1.4700 (+2.80%)
Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update GlobeNewswire - Wed Nov 6, 3:01PM CST

CHRS : 1.4700 (+2.80%)
Coherus to Report Third Quarter 2024 Financial Results on November 6, 2024 GlobeNewswire - Wed Oct 30, 3:20PM CDT

CHRS : 1.4700 (+2.80%)
Coherus BioSciences: Q2 Earnings Snapshot AP - Thu Aug 8, 3:45PM CDT

Coherus BioSciences: Q2 Earnings Snapshot

CHRS : 1.4700 (+2.80%)
Coherus BioSciences: Q1 Earnings Snapshot AP - Thu May 9, 3:12PM CDT

Coherus BioSciences: Q1 Earnings Snapshot

CHRS : 1.4700 (+2.80%)
Why Coherus Biosciences Stock Tumbled on Thursday Motley Fool - Thu Mar 14, 5:28PM CDT

The company fell well short of expectations for its fourth quarter.

CHRS : 1.4700 (+2.80%)

Barchart Exclusives

Unusual Options Volume in Palantir Puts Could Signal a Stock Peak Barchart - Wed Dec 25, 12:30PM CST
A huge, unusual volume in Palantir Technologies put options may signal a near-term peak in PLTR stock. It has doubled since its Q3 earnings on Nov. 4. However, put premiums are now very high—an income play for short-sellers. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot